Phase II study of depsipeptide [FR901228, romidepsin] in metastatic neuroendocrine tumors
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Romidepsin (Primary)
- Indications Neuroendocrine carcinoma
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Dec 2012 Planned number of patients changed from 16 to 25 as reported by ClinicalTrials.gov record.